Medical Treatment of Intracranial Atherosclerosis: An Update
Open Access
- 30 September 2017
- journal article
- review article
- Published by Korean Stroke Society in Journal of Stroke
- Vol. 19 (3), 261-270
- https://doi.org/10.5853/jos.2017.01830
Abstract
For patients with symptomatic intracranial atherosclerosis (ICAS), antithrombotic agents are the mainstay of therapy. Anticoagulation (warfarin) is not widely used since it is not more effective than aspirin and carries a high risk of bleeding. New oral anticoagulants are showing promise, but their use has not been investigated in appropriate clinical trials. Since the recurrent stroke risk is high with aspirin monotherapy, dual antiplatelets are considered in the early stage of symptomatic ICAS. Based on the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) results, aspirin plus clopidogrel has been recommended. However, this combination was not superior to aspirin monotherapy in patients with ICAS in the CHANCE substudy. Progression of ICAS is common, and it is associated with recurrent strokes. In the Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis (TOSS) study, aspirin plus cilostazol was more effective than aspirin monotherapy in preventing progression. The TOSS II trial showed that the overall change in stenosis was better with aspirin plus cilostazol than with aspirin plus clopidogrel. Aside from antithrombotic therapy, risk factor management is critical for secondary prevention, and high blood pressure is clearly linked to recurrent stroke. However, blood pressure may have to be cautiously managed in the early stage of stroke. Considering that ICAS is the major cause of stroke worldwide, further investigations are needed to establish optimal management strategies for patients with ICAS.Keywords
Funding Information
- Ministry of Health and Welfare (HI14C1985)
This publication has 64 references indexed in Scilit:
- Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic StrokeStroke, 2013
- Predictors of Recurrent Stroke in Patients With Symptomatic Intracranial Arterial StenosisStroke, 2012
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsThe New England Journal of Medicine, 2012
- Efficacy and Safety of Combination Antiplatelet Therapies in Patients With Symptomatic Intracranial Atherosclerotic StenosisStroke, 2011
- Stenting versus Aggressive Medical Therapy for Intracranial Arterial StenosisThe New England Journal of Medicine, 2011
- Risk Factors Associated With Severity and Location of Intracranial Arterial StenosisStroke, 2010
- Mild Induced Hypertension Improves Blood Flow and Oxygen Metabolism in Transient Focal Cerebral IschemiaStroke, 2008
- Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial StenosisStroke, 2005
- A review of cerebrovascular surgery in the People's Republic of China.Stroke, 1982
- XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy.Stroke, 1977